Neuroblastoma is one of the most common solid tumours to occur in children. It can be exceptionally difficult to treat and, despite intensive treatment, around one third of patients cannot currently be cured. In this project, Dr Gilham is harnessing the power of the immune system by engineering specific immune cells to destroy tumour cells. He will lay the essential groundwork in the laboratory to enable progression to clinical trial in children.
This research project on harnessing the immune system to fight cancer has been successfully completed. Your donations allow us to fund ground-breaking research that can improve treatments given to children with cancer. Thank you. Your help allows us to continue to find ways to drive up the chances of survival for children with cancer and reduce the toxic side effects that can affect the rest of their lives.
The genetics of familial leukaemia
Dr David Gilham
Paterson Institute for Cancer Research
5 November 2013